Found: 7
Select item for more details and to access through your institution.
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1231047
- By:
- Publication type:
- Article
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-a-accelerated lupus nephritis in mice.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1185727
- By:
- Publication type:
- Article
059. The Reversible Dipeptidyl Peptidase 1 Inhibitor, INS1007, Decreases Surface Proteinase 3 Expression and Neutrophil Serine Protease Activities in Human Neutrophils.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
ACHADO INCIDENTAL DE TROFOZOITOS DE Giárdia sp. ATRAVÉS DO EXAME CITOPATOLÓGICO DE INTESTINO EM CÃO: RELATO DE CASO.
- Published in:
- Acta Veterinaria Brasilica, 2023, v. 17, p. 172
- By:
- Publication type:
- Article
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
- Published in:
- Respiratory Research, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s12931-023-02444-z
- By:
- Publication type:
- Article
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1208780
- By:
- Publication type:
- Article
An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells.
- Published in:
- PLoS ONE, 2022, v. 17, n. 8, p. 1, doi. 10.1371/journal.pone.0272575
- By:
- Publication type:
- Article